Pyridylfurans and pyrroles as Raf kinase inhibitors

Details Pyridylfurans and pyrroles as Raf kinase inhibitors Pyridylfurans and pyrroles as Raf kinase inhibitors

2002-09-05

2008-11-04

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S336000, C514S343000, C544S364000, C546S276400, C546S283400

Reexamination Certificate

active

07446106

ABSTRACT:
Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.

REFERENCES:
patent: 5776954 (1998-07-01), De Laszlo et al.
patent: 5837719 (1998-11-01), de Laszlo et al.
patent: 7135550 (2006-11-01), Come et al.
patent: 2 306 108 (1997-04-01), None
patent: 2001181187 (2001-03-01), None
patent: WO 97/05878 (1997-02-01), None
patent: WO 97/16441 (1997-05-01), None
patent: WO 97/16442 (1997-05-01), None
patent: WO 97/36587 (1997-10-01), None
patent: WO 99/25717 (1999-05-01), None
patent: WO 00/01688 (2000-01-01), None
patent: WO 01/66539 (2000-09-01), None
patent: WO 00/64422 (2000-11-01), None
patent: WO 00/66124 (2000-11-01), None
patent: WO 00/69847 (2000-11-01), None
patent: WO 01/38324 (2001-05-01), None
patent: WO 01/66540 (2001-09-01), None
patent: WO 02/24680 (2002-03-01), None
patent: WO 02/057255 (2002-07-01), None
Revesz et al., SAR of 4-Hydroxypiperidine and Hydroxyalkyl Substituted Heterocycles as Novel p38 Map Kinase Inhibitors, Biorganic & Chemistry Letters, 10, pp. 1261-1264, 2000.
Lisnock et al., CAPLUS Abstract 130:308306, 1999.
Katritzky et al., CAPLUS Abstract 124:145994, 1995.
Kankare et al., CAPLUS Abstract 122:80507, 1995.
Katritzky et al., CAPLUS Abstract 113:153394, 1990.
Bhattacharjee et al., CAPLUS Abstract 94:65598, 1981.
Giridhar et al., CAPLUS Abstract 74:99815, 1971.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Keller et al., The role of Raf Kinase inhibitor protein (RKIP) in health and disease, Biochemical Pharmacology, 68, pp. 1049-1053, 2004.
Traxler, Protein Tyrosine Kinase inhibitors in cancer treatment, Exp. Opin. Ther. Patents, 7(6):571-588, 1997.
Layzer, Degenerative diseases of the nervous system, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Damasio, Alzheimer's Disease and related dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
De Laszlo et al., “Pyrroles and other heterocycles as inhibitors of p38 kinase”, Biorg. Med. Chem. Lett., vol. 8, 1998, pp. 2689-2694.
De Laszlo et al., “Potent, orally absorbed glucagon receptor antagonists”, Biorg. Med. Chem. Lett, vol. 9, 1999, pp. 641-646.
Liveton et al., “Design and Synthesis of Potent, Selective and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase”, J. Med. Chem., vol. 42, No. 12, 1999, pp. 2180-2190.
Kalmes et al., Raf-1 is activated by the p38 mitogen-activated protein kinase inhibitor, SB203580, Febs Letters, vol. 444, No. 1, 1999, pp. 71-74.
Lisnock et al., “Molecular Basis for p38 Protein Kinase Specifity”, Biochemistry, vo. 37, No. 47, 1998, pp. 16573-16581.
Cascieri et al., “Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor”, J. Biol. Chem., vol. 274, No. 13, 1999, pp. 8694-8697.

Affiliated with

Also associated with

Rating

Pyridylfurans and pyrroles as Raf kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridylfurans and pyrroles as Raf kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridylfurans and pyrroles as Raf kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4049019